Search results
Results From The WOW.Com Content Network
Last month, Cassava Sciences Inc. (NASDAQ:SAVA) agreed to pay over $40 million to resolve SEC charges over misleading statements related to a Phase 2 trial of the company’s controversial ...
(Reuters) -Cassava Sciences will form a committee to evaluatenew probes by U.S. regulators and investigate two senior employees, it said on Monday, days after a medical professor linked to the ...
WASHINGTON (Reuters) -Shares of Cassava Sciences fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the biopharmaceutical company and two former ...
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021.
About Cassava Sciences, Inc. Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive.
News. Shopping. Main Menu. News. ... but it fits the description of Cassava Sciences, which lists Wang as a consultant. ... Cassava shares surged from $7 in January 2021 to above $135 in July 2021 ...
Cassava Sciences was founded by Remi Barbier in May 1998 as Pain Therapeutics, [3] [4] focusing on opioids and chronic pain. [5] Barbier first heard of the research led by Stanley M. Crain at the Albert Einstein College of Medicine in New York City around 1993. [5]